Steroid Sulfatase: A New Target for the Endocrine Therapy of Breast Cancer

CME Activity Information
Release Date:	April 30, 2007
Most Recent Review:	April 30, 2007*
Most Recent Update:	April 30, 2007
Date Credit Expires:	April 30, 2009
Time to Complete:	1 hour
Medium:	Internet Online
*Click here to learn more about our review process.

Instructions for Participation

1. Read the following information before beginning the educational activity and click the "Take this course" link at the bottom of the page
2. Study the educational activity
3. Complete the CME quiz and evaluation
4. After successful completion of the CME quiz and evaluation, you will receive the credit or participation certificate

   *The CME quiz and evaluation must be completed by April 30, 2009, in order to receive the credit or participation certificate.

1. Discuss the role of steroid sulfatase in regulating estrogen production in postmenopausal women.
2. Describe the potential of steroid sulfatase inhibition in cancer therapy.
3. Discuss a potential new endocrine therapy for patients progressing on aromatase inhibitors.

All information is submitted and reviewed and found to be scientifically rigorous, based on the best available evidence, fair and balanced, and free of commercial bias. All the recommendations involving clinical medicine in this CME activity are based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported or used in CME in support or justification of a patient care recommendation conforms to the generally accepted standards of experimental design, data collection and analysis.

Any potential conflicts of interests are resolved via The Oncologist's anonymous peer review process: http://theoncologist.alphamedpress.org/misc/ifora.shtml. All manuscripts are reviewed by the Editorial Board with ad hoc assistance from two or more external experts in the field. All final publication decisions are made by the Editorial Board. The acceptance of a manuscript is based on its originality and importance to the field as assessed by the Editors.

Credentials: Endocrinology and Metabolic Medicine and Sterix Ltd., Imperial College, St. Mary’s Hospital, London, United Kingdom.
Disclosures: The author has indicated that they discuss the investigational new drug STX64 manufactured by Ipsen.

Patrick Delavault, M.D.

Credentials: Ipsen, Institute Henri Beaufour, Les Ulis, France.
Disclosures: The author has indicated that they discuss the investigational new drug STX64 by Ipsen. The author is also an Ipsen employee.

Atul Purohit, Ph.D.

Credentials: Endocrinology and Metabolic Medicine and Sterix Ltd., Imperial College, St. Mary’s Hospital, London, United Kingdom.
Disclosures: The author has indicated that they discuss the investigational new drug STX64 manufactured by Ipsen. The author is also an Ipsen consultant.

L.W. Laurence Woo, Ph.D.

Credentials: Medicinal Chemistry, Department of Pharmacy and Pharmacology and Sterix Ltd., University of Bath, Bath, United Kingdom.
Disclosures: The author has indicated that they discuss the investigational new drug STX64 manufactured by Ipsen. The author is also an Ipsen/Sterix project leader.

Christophe Thurieau, Ph.D.

Credentials: Ipsen, Institute Henri Beaufour, Les Ulis, France.
Disclosures: The author has indicated no relevant commercial relationships.

Barry V.L. Potter, Ph.D.

Credentials: Medicinal Chemistry, Department of Pharmacy and Pharmacology and Sterix Ltd., University of Bath, Bath, United Kingdom.
Disclosures: The author is an Ipsen/Sterix consultant.

Michael J. Reed, M.D.

Credentials: Endocrinology and Metabolic Medicine and Sterix Ltd., Imperial College, St. Mary’s Hospital, London, United Kingdom. Telephone: 44-207-886-1738; Fax: 44-207-886-1790; E-mail: m.reed{at}imperial.ac.uk.
Disclosures: The author has indicated that they discuss the investigational new drug STX64 manufactured by Ipsen. The author is also an Ipsen/Sterix consultant.

• Take this course